See full magazine here (p. 15): Link
This year we received funding for 3 different development projects:
- A new class of selective antagonistic TRPV1 for pain therapyA project we continue to get funded for.
In collaboration with KI.
- Engineering of nano-sized membrane vesicles for intracellular delivery of therapeutic antibodiesDesigning a new technology to get antibodies inside the cell
A project in collaboration with KTH, KI and SLU
- Improved cancer diagnostic and drug developmentA project in collaboration with RISE among others
Professor Owe Orwar, CEO of Oblique Therapeutics will make the first public disclosure of the company´s transformative platform for for functional antibody discovery and design at the 3rd Drug Discovery Innovation Programme 5-6 Oct 2017 Munich, Germany. Read more: https://worldbi.co.uk/DDIP/
Oblique Therapeutics has recieved a grant from the Vinnova future biological medicines program to develop functional antibodies against TRPV1 and TRPV2 for inflammatory/idiopathic pain and metastatic cancer, respectively.